| Literature DB >> 34106625 |
Qi Wang1, Xiangji Meng2, Yan Sun1, Fan Liu3, Chao Xu4,5, Yu Qiao1, Jianmei Yang1, Guimei Li1, Yulin Wang1.
Abstract
ABSTRACT: Pituitary stalk interruption syndrome (PSIS) is a rare disease associated with either isolated growth hormone deficiency (GHD) or combined pituitary hormone deficiency (CPHD). In older children and adults, most patients experience short stature or hypogonadism. Neonatal PSIS is extremely rare and is difficult to recognize due to absence of dwarfism. However, when this condition occurs in newborns, it is often life-threatening. Here, we collected patients with neonatal PSIS to clarify its characteristics to improve its early diagnosis.The patients included in this study were treated at the pediatric endocrine department of Shandong Provincial Hospital from January 2017 to July 2020. We obtained the clinical characteristics, endocrine hormone levels, pituitary magnetic resonance imaging (MRI) and further genetic data for all the patients. Hormone therapy was first given at the time of diagnosis, and the patients received regular follow-up.Three neonatal patients were identified in our clinic. The characteristics of these patients included hypoglycemia and jaundice, as well as CPHD, which included features such as micropenis and hypothyroidism. Genetic etiology was still hard to discover. All the patients responded well to alternative therapy, and the longest follow-up period was 3 years. Regular replacement ensures good prognosis.Sustained hypoglycemia and jaundice in newborns, indicate the presentation of PSIS. Early recognition is of great importance to avoid a life-threatening crisis.Entities:
Year: 2021 PMID: 34106625 PMCID: PMC8133236 DOI: 10.1097/MD.0000000000025843
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.889
Clinical characteristics of the patients with pituitary stalk interruption syndrome.
| Patient 1 | Patient 2 | Patient 3 | |
| History | |||
| Gestational, w | 40.6 | 37.5 | 39 |
| Mode of delivery | Caesarean section | Caesarean section | Caesarean section |
| Reasons for caesrean section | reduced foetal heart rate | amniotic fluid III pollution, oligohydramnios, umbilical cord around neck and torsion for 50 circles | oligohydramnios |
| Apgar (1 min/5 min) | 8/9 | 8/10 | 8/9 |
| Birth weight, kg | 3.5 | 2.45 | 2.4 |
| Clinic | |||
| Gender | Male | Male | Female |
| Age at diagnosis, d | 22 | 32 | 33 |
| Weight at diagnosis, kg | 3.6 | 3.4 | 3.17 |
| Hypoglycaemia | Yes | Yes | Yes |
| Convulsions | Yes | No | Yes |
| Jaundice | Yes | Yes | Yes |
| Micropenis | Yes | Yes | – |
| Microorchidia | Yes | Yes | – |
| Hyponatremia | Yes | No | No |
| Associated malformations | Patent ductus arteriosus | Congenital microphthalmia | No |
| MRI | |||
| Pituitary stalk | Not visible | Not visible | Not visible |
| Anterior pituitary | Not visible | Hypoplastic | Hypoplastic |
| Posterior pituitary | Not visible | Ectopic | Not visible |
| Molecular analysis | No variation | NHS | No variation |
Kg = kilogram.
Biochemical index of the patients with pituitary stalk interruption syndrome at the early onset.
| Parameters | Normal | Patient 1 | Patient 2 | Patient 3 |
| Glucose, when born, mmol/L | 3.9–6.3 | 0.4 | 2.1 | 0.9 |
| Glucose, mmol/L | 3.9–6.3 | 2.07 | 2.65 | 2.71 |
| TBIL, μmol/L | 3.5–23.5 | 123.2 | 126 | 141 |
| DBIL, μmol/L | 0.5–6.5 | 47.1 | 37.8 | 18.5 |
| IBIL, μmol/L | 1–17 | 76.1 | 87.8 | 123 |
| GGT, U/L | 7–45 | 547 | 174 | 245 |
| TBA, μmol/L | 0–12 | 110 | 67.1 | 58.5 |
| Serum sodium, mmol/L | 135–145 | 129 | 137 | 135.8 |
| Serum potassium, mmol/L | 3.5–5.5 | 4.90 | 1.76 | 5.25 |
| TSH, μIU/ml | 0.64–6.27 | 0.008 | 7.67 | 9.81 |
| FT3, pmol/L | 3.5–6.5 | 2.99 | 3.65 | 4.35 |
| FT4, pmol/L | 11.5–22.7 | 17.0 | 9.76 | 10.4 |
| ACTH, pg/ml | 7.2–63.3 | 1.65 | 31.3 | 19.9 |
| Cor, pg/ml | 172–497 | 42.4 | 34.3 | 16.9 |
| GH, ng/ml | 0.09–6.29 | <0.03 | 6.18 | 4.45 |
| IGF-1, ng/ml | – | <25 | Not done | 25.7 |
| FSH, mIU/ml | 1.5–12.4 | 0.11 | 0.15 | 0.20 |
| LH, mIU/ml | 1.7–8.6 | <0.10 | <0.10 | <0.10 |
| Testosterone, mIU/ml | 0.12–0.21 | <0.03 | <0.03 | <0.50 |
| E2, pg/ml | 12.4–233 | Not done | Not done | < 5 |
| Blood ammonia, μmol/L | 3–47 | 50.0 | 70.0 | 67 |
ACTH = adrenocorticotropic hormone, COR = cortisol, DBIL = direct bilirubin, E2 = estrogen, FSH = follicle- stimulating hormone, FT3 = free triiodothyronine, FT4 = free thyroxine, GGT = gamma- glutamyltransferase, GH = growth hormone, IBIL = indirect bilirubin, IGF-1 = insulin-like growth factor-1, LH = luteinizing hormone, TBA = total serum bile acid, TBIL = total bilirubin, TSH = thyroid stimulating hormone.
Figure 1Magnetic resonance imaging (MRI) scan of the pituitary in our patients. Patient 1: The sagittal image showed that no pituitary was found in the pituitary fossa, the pituitary stalk was not seen, and the hyperintense signal disappeared in the posterior pituitary. Patient 2: The sagittal image showed that the anterior pituitary was slightly lower, the pituitary stalk could not be seen clearly, and posterior pituitary ectopia as well as bilateral lateral ventricle widening. Patient 3: The sagittal image showed that the anterior pituitary was slightly lower, the pituitary stalk was not seen, and the hyperintense signal disappeared in the posterior pituitary.
Biochemical index of the patients with pituitary stalk interruption syndrome in the last follow-up.
| Parameters | Normal | Patient 1 | Patient 2 | Patient 3 |
| Glucose, mmol/L | 3.9–6.3 | 4.98 | 4.99 | 5.24 |
| TBIL, μmol/L | 3.5–23.5 | 8.64 | 8.14 | 14.2 |
| DBIL, μmol/L | 0.5–6.5 | 1.66 | 1.50 | 2.00 |
| IBIL, μmol/L | 1–17 | 6.98 | 6.64 | 12.2 |
| GGT, U/L | 7–45 | 9.00 | 11.0 | 12.0 |
| TBA, μmol/L | 0–12 | 1.40 | 1.54 | 1.59 |
| Serum sodium, mmol/L | 135–145 | 137 | 134 | 139 |
| Serum potassium, mmol/L | 3.5–5.5 | 4.54 | 4.40 | 4.30 |
| TSH, μIU/ml | 0.64–6.27 | <0.005 | 0.016 | 0.120 |
| FT3, pmol/L | 3.5–6.5 | 4.94 | 5.17 | 4.82 |
| FT4, pmol/L | 11.5–22.7 | 12.4 | 20.5 | 12.5 |
| ACTH, pmol/L | 7.2–63.3 | 2.97 | 3.46 | 3.32 |
| Cor, nmol/L | 172–497 | 335 | 316 | 378 |
| IGF-1, ng/ml | – | 248 | 172 | 155 |
| FSH, mIU/ml | 1.5–12.4 | <0.10 | Not done | Not done |
| LH, mIU/ml | 1.7–8.6 | <0.10 | Not done | Not done |
| Testosterone, ng/mL | 0.12–0.21 | 0.04 | Not done | / |
ACTH = adrenocorticotropic hormone, COR = cortisol, DBIL = direct bilirubin, FSH = follicle- stimulating hormone, FT3 = free triiodothyronine, FT4 = free thyroxine, GGT = gamma-glutamyltransferase, IBIL = indirect bilirubin, IGF-1 = insulin-like growth factor-1, LH = luteinizing hormone, TBA = total serum bile acid, TBIL = total bilirubin, TSH = thyroid stimulating hormone.